-
1
-
-
0034644539
-
Cell signaling by receptor tyrosine kinases
-
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211-25.
-
(2000)
Cell
, vol.103
, pp. 211-225
-
-
Schlessinger, J.1
-
2
-
-
0035902180
-
Oncogenic kinase signalling
-
Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
-
(2001)
Nature
, vol.411
, pp. 355-365
-
-
Blume-Jensen, P.1
Hunter, T.2
-
3
-
-
2342591455
-
The discovery of receptor tyrosine kinases: Targets for cancer therapy
-
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
4
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011;144:646-74.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
5
-
-
12944271053
-
Cancer statistics, 2005
-
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 10-30
-
-
Jemal, A.1
Murray, T.2
Ward, E.3
Samuels, A.4
Tiwari, R.C.5
Ghafoor, A.6
-
6
-
-
84882289352
-
-
American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society; 2010
-
American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: American Cancer Society; 2010.
-
-
-
-
7
-
-
52249116587
-
EGFR-targeted therapeutics: Focus on SCCHN and NSCLC
-
Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: Focus on SCCHN and NSCLC. Sci World J 2008;8:909-19.
-
(2008)
Sci World J
, vol.8
, pp. 909-919
-
-
Sattler, M.1
Abidoye, O.2
Salgia, R.3
-
9
-
-
77958478674
-
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
-
Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10: 760-74.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 760-774
-
-
Pao, W.1
Chmielecki, J.2
-
10
-
-
34249075147
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
-
(2007)
Science
, vol.316
, pp. 1039-1043
-
-
Engelman, J.A.1
Zejnullahu, K.2
Mitsudomi, T.3
Song, Y.4
Hyland, C.5
Park, J.O.6
-
11
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3: 75ra26.
-
(2011)
Sci Transl Med
, vol.3
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
Digumarthy, S.4
Turke, A.B.5
Fidias, P.6
-
12
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
Riely, G.4
Viale, A.5
Wang, L.6
-
13
-
-
84855543629
-
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
-
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012;18:74-82.
-
(2012)
Nat Med
, vol.18
, pp. 74-82
-
-
Garofalo, M.1
Romano, G.2
Di Leva, G.3
Nuovo, G.4
Jeon, Y.J.5
Ngankeu, A.6
-
14
-
-
0345601083
-
Met, metastasis, motility and more
-
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
-
(2003)
Nat Rev Mol Cell Biol
, vol.4
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
Vande Woude, G.F.4
-
15
-
-
64849102583
-
Role of c-Met in cancer: Emphasis on lung cancer
-
Salgia R. Role of c-Met in cancer: Emphasis on lung cancer. Semin Oncol 2009;36:S52-8.
-
(2009)
Semin Oncol
, vol.36
-
-
Salgia, R.1
-
16
-
-
78649420006
-
MET signalling: Principles and functions in development, organ regeneration and cancer
-
Trusolino L, Bertotti A, Comoglio PM. MET signalling: Principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
-
(2010)
Nat Rev Mol Cell Biol
, vol.11
, pp. 834-848
-
-
Trusolino, L.1
Bertotti, A.2
Comoglio, P.M.3
-
18
-
-
36849065315
-
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
-
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
-
(2007)
Cell
, vol.131
, pp. 1190-1203
-
-
Rikova, K.1
Guo, A.2
Zeng, Q.3
Possemato, A.4
Yu, J.5
Haack, H.6
-
21
-
-
76749157917
-
Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency
-
McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-34.
-
(2010)
Cancer Res
, vol.70
, pp. 1625-1634
-
-
McDermott, U.1
Pusapati, R.V.2
Christensen, J.G.3
Gray, N.S.4
Settleman, J.5
-
22
-
-
77956296140
-
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth
-
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70:6880-90.
-
(2010)
Cancer Res
, vol.70
, pp. 6880-6890
-
-
Zhang, Y.W.1
Staal, B.2
Essenburg, C.3
Su, Y.4
Kang, L.5
West, R.6
-
23
-
-
19944430738
-
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor
-
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005;24:101-6.
-
(2005)
Oncogene
, vol.24
, pp. 101-106
-
-
Zhang, Y.W.1
Su, Y.2
Lanning, N.3
Gustafson, M.4
Shinomiya, N.5
Zhao, P.6
-
24
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
25
-
-
33947207989
-
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival
-
Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8.
-
(2007)
Cancer Res
, vol.67
, pp. 2081-2088
-
-
Lutterbach, B.1
Zeng, Q.2
Davis, L.J.3
Hatch, H.4
Hang, G.5
Kohl, N.E.6
-
26
-
-
73149091443
-
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
-
Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009;8:3181-90.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 3181-3190
-
-
Buchanan, S.G.1
Hendle, J.2
Lee, P.S.3
Smith, C.R.4
Bounaud, P.Y.5
Jessen, K.A.6
-
27
-
-
80052511675
-
Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC
-
(suppl; abstr 7505)
-
Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7505).
-
(2011)
J Clin Oncol
, vol.29
-
-
Spigel, D.R.1
Ervin, T.J.2
Ramlau, R.3
Daniel, D.B.4
Goldschmidt, J.H.5
Blumenschein, G.R.6
-
28
-
-
80051974548
-
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer
-
Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-15.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3307-3315
-
-
Sequist, L.V.1
Von Pawel, J.2
Garmey, E.G.3
Akerley, W.L.4
Brugger, W.5
Ferrari, D.6
-
29
-
-
62549161686
-
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
-
Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer 2009;100: 941-9.
-
(2009)
Br J Cancer
, vol.100
, pp. 941-949
-
-
Agarwal, S.1
Zerillo, C.2
Kolmakova, J.3
Christensen, J.G.4
Harris, L.N.5
Rimm, D.L.6
-
30
-
-
84860214990
-
Intra-tumour heterogeneity: A looking glass for cancer?
-
Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 323-334
-
-
Marusyk, A.1
Almendro, V.2
Polyak, K.3
-
31
-
-
84882246949
-
-
MetMAb Significantly Enhances Anti-tumor Activity Of Anti-VEGF And Or Erlotinib In Several Animal Tumor Models. Oct 21-24; Geneva (Switzerland): Abstract nr 556
-
Merchant M, Zhang Y, Su Y, Romero M, Severin C, Zheng Z, et al. MetMAb significantly enhances anti-tumor activity of anti-VEGF and/or erlotinib in several animal tumor models. Presented at the 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2008 Oct 21-24; Geneva (Switzerland): Abstract nr 556.
-
(2008)
Presented at the 20th Annual AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
-
-
Merchant, M.1
Zhang, Y.2
Su, Y.3
Romero, M.4
Severin, C.5
Zheng, Z.6
|